Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
High-impact clinical trial results could improve kidney-related medical care

High-impact clinical trial results could improve kidney-related medical care

Researcher is exploring safer and more effective treatment for leukemia

Researcher is exploring safer and more effective treatment for leukemia

Novel compound shows promise for ANCA-associated vasculitis

Novel compound shows promise for ANCA-associated vasculitis

Drug combo for untreated CLL approved by FDA based on E1912 trial

Drug combo for untreated CLL approved by FDA based on E1912 trial

Immunotherapy before surgery may help eradicate high-risk breast cancer

Immunotherapy before surgery may help eradicate high-risk breast cancer

Study provides new evidence about optimal way to treat BRCA carriers with breast cancer

Study provides new evidence about optimal way to treat BRCA carriers with breast cancer

Catastrophic macropinocytosis may aid in cancer treatment

Catastrophic macropinocytosis may aid in cancer treatment

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Researchers confirm two new prognostic markers for triple negative breast cancer

Researchers confirm two new prognostic markers for triple negative breast cancer

Adding post-transplant chemotherapy to standard treatment improves remission of allogeneic transplant patients

Adding post-transplant chemotherapy to standard treatment improves remission of allogeneic transplant patients

Nab-Paclitaxel drug combo reduces risk of  breast cancer recurrence

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

Large doses of traditional chemotherapy drug spur immune system attack on cancer cells

Large doses of traditional chemotherapy drug spur immune system attack on cancer cells

Scientists develop new test to examine a drug's embryotoxicity in cell cultures

Scientists develop new test to examine a drug's embryotoxicity in cell cultures

Deadly inherited blood disorders cured with bone marrow transplant

Deadly inherited blood disorders cured with bone marrow transplant

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program